| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Charles F Reynold. Paroxetine treatment of depression in late life. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566207. |
first-line treatment options include selective serotonin reuptake inhibitors (ssris), one of which, paroxetine, has been studied extensively in older adults. |
2004-01-28 |
2023-08-12 |
Not clear |
| Robert N Golde. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566210. |
paroxetine controlled-release (cr) was developed with the objective of minimizing the occurrence and severity of selective serotonin reuptake inhibitor (ssri)-associated adverse events, thereby improving clinical outcomes. |
2004-01-28 |
2023-08-12 |
Not clear |
| Violetta Klimek, Gary Roberson, Craig A Stockmeier, Gregory A Ordwa. Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. Journal of psychiatric research. vol 37. issue 5. 2004-01-22. PMID:12849931. |
the specific binding of [(3)h]paroxetine to serotonin transporter (sert) and of [(3)h]lazabemide to monoamine oxidase (mao-b) were measured autoradiographically in tissue sections cut transversely at multiple levels along the rostro-caudal extent of the lc, as well as in the caudal portion of the dorsal raphe nucleus, from psychiatrically normal subjects and age-matched subjects with major depression. |
2004-01-22 |
2023-08-12 |
human |
| Karine Titier, Nadège Castaing, Emmanuelle Scotto-Gomez, Fabienne Pehourcq, Nicholas Moore, Mathieu Molimar. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. Therapeutic drug monitoring. vol 25. issue 5. 2004-01-05. PMID:14508381. |
a high-performance liquid chromatographic method is described for the determination of selective serotonin reuptake inhibitors (fluvoxamine, paroxetine, sertraline, fluoxetine, citalopram, mirtazapine), serotonin norepinephrine reuptake inhibitors (milnacipram, venlafaxine), a noradrenergic and specific serotoninergic antidepressant (mirtazapine), and five pharmacologically active metabolites (desmethylcitalopram, didesmethylcitalopram, norfluoxetine, o-desmethylvenlafaxine, desmethylmirtazapine). |
2004-01-05 |
2023-08-12 |
Not clear |
| Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhar. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute. vol 95. issue 23. 2004-01-05. PMID:14652237. |
active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. |
2004-01-05 |
2023-08-12 |
Not clear |
| Sandra Payton, Catherine M Cahill, Jeffrey D Randall, Steven R Gullans, Jack T Roger. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. Journal of molecular neuroscience : MN. vol 20. issue 3. 2003-12-23. PMID:14501007. |
in this report, we show that paroxetine (serotonin reuptake blocker) and dimercaptopropanol (hg chelator) exerted significant effects on app expression (steady-state levels of app), whereas azithromycin altered app processing. |
2003-12-23 |
2023-08-12 |
Not clear |
| Dan J Stein, Jonathan Davidson, Soraya Seedat, Katherine Beeb. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert opinion on pharmacotherapy. vol 4. issue 10. 2003-12-18. PMID:14521492. |
paroxetine is a selective serotonin re-uptake inhibitor that has been found effective in the treatment of major depression as well as a range of anxiety disorders. |
2003-12-18 |
2023-08-12 |
Not clear |
| Vanessa Beijamini, Roberto Andreatin. Effects of Hypericum perforatum and paroxetine in the mouse defense test battery. Pharmacology, biochemistry, and behavior. vol 74. issue 4. 2003-12-15. PMID:12667917. |
paroxetine (5 mg/kg), a selective serotonin re-uptake inhibitor with anxiolytic and antipanic effect, was used as a positive control. |
2003-12-15 |
2023-08-12 |
mouse |
| Elsebet Steno Hansen, Steen Hasselbalch, Ian Law, Tom G Bolwi. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. The international journal of neuropsychopharmacology. vol 5. issue 1. 2003-12-12. PMID:12057027. |
patients were studied before and after 12-20 wk of treatment with the serotonin re-uptake inhibitor paroxetine. |
2003-12-12 |
2023-08-12 |
Not clear |
| Paroxetine: new indication. In generalised anxiety: uncertain efficacy. Prescrire international. vol 12. issue 67. 2003-11-26. PMID:14619895. |
(3) in france, generalised anxiety has now been added to the licensed indications of paroxetine, a "selective" serotonin reuptake inhibitor antidepressant. |
2003-11-26 |
2023-08-12 |
Not clear |
| Bruce R Lawford, Ross McD Young, Ernest P Noble, Burnett Kann, Leanne Arnold, John Rowell, Terry L Ritchi. D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 13. issue 5. 2003-11-03. PMID:12957328. |
this study examined whether allelic status of the d2 dopamine receptor (drd2) gene was associated with response to a selective serotonin reuptake inhibitor, paroxetine, in the treatment of posttraumatic stress disorder (ptsd). |
2003-11-03 |
2023-08-12 |
Not clear |
| Andrew Harkin, Eamonn Shanahan, John P Kelly, Thomas J Conno. Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. The European journal of neuroscience. vol 18. issue 4. 2003-10-14. PMID:12925028. |
mda pretreatment resulted in 5-ht nerve terminal degeneration, indicated by reduced 5-ht and 5-hiaa concentrations in the frontal cortex, amygdala and hippocampus, and reduced [3h]paroxetine binding in the frontal cortex. |
2003-10-14 |
2023-08-12 |
rat |
| Nadège Ripoll, Denis Joseph Paul David, Eric Dailly, Martine Hascoët, Michel Bouri. Antidepressant-like effects in various mice strains in the tail suspension test. Behavioural brain research. vol 143. issue 2. 2003-10-07. PMID:12900045. |
for this study four mice strains (swiss and nmri, two outbred strains and dba/2 and c57bl/6j rj, two inbred strains) were submitted to the tst after acute administration of five antidepressants: the tricyclic antidepressants (tcas) imipramine and desipramine, the selective serotonin (5-ht) reuptake inhibitors (ssris) paroxetine and citalopram and the dopamine reuptake inhibitor bupropion. |
2003-10-07 |
2023-08-12 |
mouse |
| Nadège Ripoll, Denis Joseph Paul David, Eric Dailly, Martine Hascoët, Michel Bouri. Antidepressant-like effects in various mice strains in the tail suspension test. Behavioural brain research. vol 143. issue 2. 2003-10-07. PMID:12900045. |
the nmri and dba/2 mice only responded to 5-ht reuptake inhibitors, both selective (paroxetine, citalopram) or non-selective (imipramine). |
2003-10-07 |
2023-08-12 |
mouse |
| Georgianna G Gould, Marie-Christine Pardon, David A Morilak, Alan Fraze. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 9. 2003-10-06. PMID:12825093. |
to study this, we examined changes in binding sites in rat brain for norepinephrine (net) and serotonin transporters (sert), alpha1, alpha2, and beta1 adrenergic receptors after chronic administration of paroxetine (prx), reboxetine (rbx), or prx followed by rbx. |
2003-10-06 |
2023-08-12 |
rat |
| Carla E Ramacciotti, Elisabetta Coli, Riccardo Paoli, Donatella Marazziti, Liliana Dell'Oss. Serotonergic activity measured by platelet [3H]paroxetine binding in patients with eating disorders. Psychiatry research. vol 118. issue 1. 2003-10-03. PMID:12759159. |
although ed patients share a dysregulation in serotonergic activity, dsm-iv subtype classification was not validated by [3h]paroxetine binding, and hence does not correspond to a specific 5-ht profile. |
2003-10-03 |
2023-08-12 |
Not clear |
| A Balcioglu, K Zhang, F I Taraz. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience. vol 119. issue 4. 2003-09-05. PMID:12831863. |
basal levels of [(3)h]paroxetine binding to 5-ht transporters in caudate-putamen increased by 41% in 6-ohda-lesioned animals. |
2003-09-05 |
2023-08-12 |
rat |
| Nobuhisa Ueda, Reiji Yoshimura, Koji Shinkai, Yumi Sakata, Jun Nakamur. Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea. Neuropsychobiology. vol 48. issue 1. 2003-09-02. PMID:12886038. |
we investigated the association between selective serotonin reuptake inhibitors (ssris; paroxetine or fluvoxamine) and nausea with regard to plasma 5-hydroxyindoleacetic acid (p5-hiaa) levels. |
2003-09-02 |
2023-08-12 |
Not clear |
| Paroxetine: new indication. In social phobia: minimal assessment. Prescrire international. vol 12. issue 66. 2003-08-28. PMID:12906023. |
paroxetine is the best assessed selective serotonin reuptake inhibitor in this setting. |
2003-08-28 |
2023-08-12 |
Not clear |
| Kirk M Bertelsen, Karthik Venkatakrishnan, Lisa L Von Moltke, R Scott Obach, David J Greenblat. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug metabolism and disposition: the biological fate of chemicals. vol 31. issue 3. 2003-08-27. PMID:12584155. |
paroxetine, a selective serotonin reuptake inhibitor, is a potent inhibitor of cytochrome p450 2d6 (cyp2d6) activity, but the mechanism of inhibition is not established. |
2003-08-27 |
2023-08-12 |
human |